指南与共识神经技术与安全MR

实践现状:美国神经放射学会关于慢性肾脏病患者使用钆基对比剂的声明

State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease.
指南 / 共识 · AJNR Am J Neuroradiol · 2025-02-03

美国神经放射学会标准与指南委员会于2023至2024年回顾近5年系统综述与Meta分析,针对慢性肾脏病患者钆基对比剂使用提出推荐:神经影像中若医学上需要诊断,不应再停用II组钆基对比剂;若影像实践仅使用II组钆基对比剂,可停止检查肾功能或询问患者慢性肾脏病等其他安全措施。

要点

  • 神经影像中医学需要时,II组钆基对比剂不再因慢性肾脏病而停用。
  • 若影像实践仅使用II组钆基对比剂,可停止检查肾功能或询问慢性肾脏病。
  • 自2006年后全球肾源性系统纤维化发生率大幅下降,II组药物相关无混杂病例少。

核心结论

  • 美国神经放射学会推荐:神经影像中医学需要诊断时,II组钆基对比剂不再对慢性肾脏病患者停用;若影像实践仅使用II组钆基对比剂,可停止检查肾功能或询问慢性肾脏病等其他安全措施。

研究设计与样本

  • 美国神经放射学会标准与指南委员会于2023至2024年回顾近5年关于钆基对比剂安全性的系统综述与Meta分析,据此形成慢性肾脏病患者钆基对比剂使用推荐。

诊断标准与关键数值

  • 美国放射学会分类为II组的钆基对比剂相关无混杂肾源性系统纤维化病例少。
  • 神经影像中医学需要诊断时,推荐不再对慢性肾脏病患者停用II组钆基对比剂。
  • 若影像实践仅使用II组钆基对比剂,可停止检查肾功能或询问患者慢性肾脏病等其他安全措施。

临床应用与阅片要点

  • 神经影像中医学需要诊断时,II组钆基对比剂不再因慢性肾脏病而停用。
  • 若影像实践仅使用II组钆基对比剂,可停止检查肾功能或询问患者慢性肾脏病等其他安全措施。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Beginning in 2006, neuroradiologists became increasingly aware of the risk of nephrogenic system fibrosis (NSF) when patients with chronic kidney disease (CKD) received gadolinium-based contrast agents (GBCAs) in conjunction with MRI scans. Radiology practices began withholding GBCAs from MRI patients with substantial CKD and instated a variety of safety measures to ensure that these individuals did not inadvertently receive GBCAs. As a result, the worldwide incidence of NSF was dramatically reduced. Since that time, a wealth of research on NSF and its etiology has found few unconfounded cases associated with those GBCAs categorized as group II agents by the American College of Radiology.

METHODS: In 2023 and 2024, members of the American Society of Neuroradiology (ASNR) Standards and Guidelines Committee reviewed new research evidence on GBCA safety and its relevance to current MRI contrast administration guidelines for patients with CKD. This focused on systematic reviews and meta-analyses conducted during the past 5 years. Upon consideration of this literature, recommendations for the administration of GBCAs to patients with CKD were formulated.

KEY MESSAGE: For neuroimaging applications, the ASNR recommends that group II GBCAs no longer be withheld in patients with CKD when these agents are medically indicated for diagnosis. Moreover, if group II GBCAs are exclusively used in an MRI practice, other safety measures, such as checking renal function or querying patients about CKD, can be discontinued.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Welker KM, Joyner D, Kam AW, et al. State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease. AJNR Am J Neuroradiol. 2025. PMID: 39284636. doi:10.3174/ajnr.A8501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。